Doug Wintemute is a staff writer for Forbes Advisor. After completing his master’s in English at York University, he began his writing career in the higher education space. Over the past decade, Doug ...

Novartis has reached an agreement to buy Regulus Therapeutics and its experimental therapy for autosomal dominant polycystic kidney disease (ADPKD) for $800 million upfront in a deal that could have a ...

How Trump and Musk’s spending cuts are hampering US government readiness amid the Iran war Cuts to programs and personnel at federal agencies that had been declared ...

The hardest part of working out consistently? Getting started. Once you do, though, you start feeling (and soon, seeing!) the positive impact on your mind and body. But with so many workout options ...